[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:ganglioside-gd2":3},{"name":4,"total":5,"recruiting":5,"trials":6},"Ganglioside GD2",5,[7,15,22,28,35],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05489887","Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma",[11],"Phase 2","RECRUITING","2026-08-26T02:19:16.454910Z","2026-07-05T05:32:16.806484Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT03721068","Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed\u002FRefractory Neuroblastoma or Relapsed\u002FRefractory Osteosarcoma",[19],"Phase 1","2026-08-26T02:19:19.162260Z","2026-05-05T02:43:28.120445Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT07211737","NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma",[19],"2026-08-26T02:19:23.493898Z","2026-05-05T02:43:27.839814Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":33,"content_modified":34},"NCT05620342","Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer",[32],"Early Phase 1","2026-08-26T02:18:20.384845Z","2026-04-29T02:57:57.150617Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":39,"content_modified":40},"NCT04099797","C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)",[19],"2026-08-26T02:16:22.235886Z","2026-05-05T02:43:27.089113Z"]